SARS-cov2(COVID-19). COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Includes 40 patients with COVID-19 for 5 days, hydroxychloroquine sulfate tablets with lopinavir / ritonavir tablets of 200/50 mg, 2 tablets every 12 hours, or 400
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 18 years of age or older Diagnosis of COVID-19 by RT PCR and CT scan of the lungs Blood oxygen levels are between 90 and 93 percent Breathing rate between 20 and 24 per minute Heart rate between 100 and 130 beats per minute
Exclusion criteria
Exclusion criteria: Intubation (mechanical ventilation) Shortness of breath caused by cardiogenic pulmonary edema Pregnancy and lactation Patients with end stage, lung, malignant, G6PD deficiency, diabetic ketoacidosis, cardiac arrhythmia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response. Timepoint: During hospitalizatio. Method of measurement: Cessation of fever, improvement of shortness of breath, reduction of cough, blood oxygenation (SaO2) and hemodynamic parameters.;Mortality. Timepoint: During hospitalizatio. Method of measurement: Count the number of dead patients.;Hospital stay. Timepoint: During hospitalizatio. Method of measurement: Count the number of hospital days to improve clinical symptoms. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAtousa Hakamifard
Esfahan University of Medical Sciences
Outcome results
None listed